The researchers compared samples of follow-on and compounded products with the originator semaglutide and liraglutide products. Our review of funding in GLP-1 studies explains how to read disclosures alongside study methods. This comparison was conducted by researchers affiliated with the originator manufacturer.
Who did the work
Nine authors disclosed that they were employees and shareholders of Novo Nordisk, the manufacturer of the originator products. The tenth disclosed that he was a shareholder and worked at Novo Nordisk when the study was conducted[1].
What they found
Follow-on drug substance, follow-on products and compounded products all showed impurity profiles distinct from the originators: amino acid deletions and additions, and impurities the analysis could not identify. A patient can verify the dispensing pharmacy before filling a prescription, though that check cannot establish what is in a specific vial.
Exposed to light, compounded semaglutide differed significantly from the originator on strength, total impurities and high-molecular-weight protein content. The liraglutide follow-ons had reduced physical stability.
What to ask the dispensing pharmacy
Ask the pharmacy how to store your prescription and what to do if a shipment arrives outside the stated storage conditions. The guide to compounded semaglutide safety describes evidence on dispensing and labeling. The laboratory study examined specific samples and does not establish how every compounded product behaves.
Ask the pharmacist to show you how to measure your prescribed dose. The guide to vial dosing errors explains why concentration and syringe markings matter. Dosing errors are a separate issue from the impurities measured in this study.